List view / Grid view
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved…
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first dual-combination, inhaled corticosteroid and long-acting beta2-agonist reliever therapy for mild asthma.
The first PARP inhibitor to show clinical benefit with a…
The first PARP inhibitor to show clinical benefit with a new hormonal agent in first-line metastatic castration-resistant prostate cancer has been granted UK approval.
The MHRA has approved dapagliflozin for chronic heart failure across…
The MHRA has approved dapagliflozin for chronic heart failure across the full spectrum of left ventricular ejection fraction.
